Placental Stem Cell Populations
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 11/648,804, filed Dec 28, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,078,898 | Placental Stem Cell Populations In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | ||
| US 10,383,897 | Placental Stem Cell Populations In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | ||
| US 8,202,703 | Placental Stem Cell Populations In force · High confidence | Celeniv Pte. Ltd. | In force | High confidence | ||
| US 8,591,883 | Placental Stem Cell Populations Lapsed Nov 26, 2025 on the fee record Ended Nov 26, 2025 · High confidence | Celeniv Pte. Ltd. | Lapsed Nov 26, 2025 on the fee record | Ended Nov 26, 2025 | High confidence | |
| US 8,691,217 | Placental Stem Cell Populations Lapsed Apr 8, 2026 on the fee record Ended Apr 8, 2026 · High confidence | Celeniv Pte. Ltd. | Lapsed Apr 8, 2026 on the fee record | Ended Apr 8, 2026 | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Celeniv Pte. Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.